novo nordisk semaglutide fda Wegovy® A New Era of Weight

Semaglutide dose Among 715 patients with no type 2 diabetes diagnosis, 353 (49%) had a high documented semaglutide dose of either 1.7 mg, 2.0 mg, or 2.4 mg, compared with only 116 (15%) of 767 patients with type 2 diabetes ( Figure 1 )

However, one 2017 study found BPC-157 actually reduced tumor growth by 45% in colon cancer models (Tkalcevic et al., 2017)

Accordingly, mediation analysis of LEADER and SUSTAIN-6 suggested that HbA1c and SBP lowering might partially mediate the GLP-1RA renal benefits

#HealthTips #MedicalInfo #PainRelief #FeverRelief #KnowYourMeds #OTCmeds #OTC #Paracetamol #Ibuprofen #Aspirin #Wellness #HealthEducation #SelfCare #Viral #Trending To view or add a comment, sign in NATCO Rolls Out Affordable Generic Semaglutide for Type 2 Diabetes in India #NATCOPharma #Semaglutide #Type2Diabetes #GLP1 #GenericDrugs #DiabetesCare #IndiaPharma #AffordableMedicines #MetabolicHealth #DrugLaunch #PharmaNews #HealthcareAccess To view or add a comment, sign in During my past 6 months many of my diabetes and obesity cases have benefitted from the existing Glp1 agonists on uae mainly ozempic mounjaro and rybelsus(worlds first oral Glp1).Today there was a press statement that Eli Lilly foundayo (orforglipron) has been approved for use in uae for weight loss management and obesity #obesity Hope the cost is similar to rybelsus and hope approvals for the drug are not cumbersome.I always like to be update on newer molecules in diabetes and obesity

GLP-1 medications can be effective while a patient is actively taking them

Organ Protection : BPC-157 reduces oxidative stress and inflammatory markers in liver, kidney, and cardiac tissue following toxic exposure